Privia Health Group (NASDAQ:PRVA) disclosed that its executive vice president and chief financial officer, David Mountcastle, sold 5,566 shares of the company’s common stock on April 2, 2026, at a price of $20.85 per share. The sale generated proceeds of approximately $116,051 and the company said the transaction was executed to meet tax obligations related to the vesting of restricted stock units.
Following the disposition, Mountcastle retains direct ownership of 214,847 shares and indirect ownership of 8,695 shares through his spouse. No additional changes to his holdings were reported in the disclosure accompanying the transaction.
In separate developments, several sell-side firms updated their assessments of Privia Health in light of the company’s fourth-quarter 2025 results and 2026 guidance, which the firms said outperformed expectations on measures including revenue and adjusted EBITDA.
Piper Sandler raised its price target on Privia Health to $36.00 while keeping an Overweight rating, citing the company’s fourth-quarter results and forward guidance as the basis for the move. Jefferies followed with an increase to its target, lifting it from $30 to $32 and pointing to a fourth-quarter performance that beat expectations.
Truist Securities maintained a Buy rating and set a price target of $33.00 after meetings with the company’s senior vice president of investor relations and corporate communications. Citizens also reaffirmed a Market Outperform rating with a $31.00 price target, and noted that its full-year adjusted EBITDA estimates for 2026 and 2027 remain unchanged after correcting a prior calculation error.
Within analysts’ commentary, Piper Sandler’s review of MSSP-related data emphasized a 38.7% year-over-year increase in adjusted EBITDA for 2025, even as the company navigated difficulties within its largest MSSP accountable care organization (ACO). Collectively, these actions from multiple firms reflect an improved analyst tone regarding Privia Health’s recent financial performance and prospects.
The transaction by Mountcastle was described specifically as related to tax obligations from vesting restricted stock units; the disclosure did not indicate any other motivations or additional planned sales. The analyst revisions and reaffirmations are tied in public notes and meeting feedback to the company’s reported results and guidance for the periods referenced.